Evidence map›Paper›PMID 39608749›Full record

ArticleContemporary clinical trials2025

The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease.

Jesse C Christensen, Shuchi Anand, Glenn M Chertow, Kate Lyden, Amara Sarwal, Terrence Bjordahl, Robert Boucher, Azeem Mohammed, Evan G Oro, Farahnaz Akramimoghaddam and 9 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jesse C ChristensenDepartment of Physical Therapy & Athletic Training, University of Utah, College of Health, Salt Lake City, UT, USA; Physical Medicine and Rehabilitation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA. Electronic address: jesse.christensen@hsc.utah.edu.
Shuchi AnandDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Glenn M ChertowDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Kate LydenKAL Research and Consulting, LLC, Denver, CO, USA.
Amara SarwalDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Terrence BjordahlDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Robert BoucherDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Azeem MohammedDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Evan G OroDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Farahnaz AkramimoghaddamDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Niharika KatkamDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Augustine TakyiDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
George BissadaDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Akhil Ramanujam ChakravartulaDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA.
Edison LeeDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Ann ZhengDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Guo WeiDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA; Division of Biostatistics, Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.
Tom GreeneDivision of Biostatistics, Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA; Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Srinivasan BeddhuDivision of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Cardio-Renal & Metabolism Center, University of Utah School of Medicine, Salt Lake City, UT, USA; Medical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.

Funding

CTSA UM1 Program at University of UtahUM1TR004409 · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2025 to 2025
$5.4M
Sit Less, Interact and Move More (SLIMM) 2 StudyR01DK128640 · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2025 to 2025
$636k
Objectively Measured Sedentary Behavior and Physical Activity in PREVENTABLE StudyR01AG074592 · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2025 to 2025
$519k
NCATS NIH HHS UM1 TR004409NIA NIH HHS R01 AG074592NIDDK NIH HHS R01 DK128640
6 · The paper itself

Abstract

backgroundSedentary behavior is highly prevalent and associated with morbidity and mortality in chronic kidney disease (CKD). A Sit Less, Interact and Move More (SLIMM) sedentary activity coaching intervention can reduce sedentary duration among persons with CKD, but preliminary data suggest that effects may not persist. Prior studies have suggested that moderate/vigorous intensity physical activities are not sustainable in persons with CKD. Therefore, we aimed to determine whether guided resistance training ± oral semaglutide co-intervention improves adherence and/or persistence of the SLIMM intervention. METHOD/

designThe SLIMM-2 is a two-center study designed with a 3-month sedentary activity coaching (SLIMM) followed by a 9-month randomized controlled trial with three arms: SLIMM + standard of care resistance training + oral placebo, SLIMM + guided resistance training + oral placebo, or SLIMM + guided resistance training + oral semaglutide. The study is recruiting persons with CKD (eGFR 20 to ≤60 ml/min/1.73 m

resultsEnrollment, interventions, and follow-up are ongoing.

conclusionsResults from the SLIMM-2 study are expected to inform clinical practice, with the potential to enhance physical health and functioning among persons with CKD.

Indexed as

Glucagon-Like PeptidesRenal Insufficiency, ChronicResistance TrainingSedentary BehaviorAccelerometryExerciseFemaleGlucagon-Like Peptide 1HumansHypoglycemic AgentsMaleMiddle AgedMulticenter Studies as TopicPatient ComplianceRandomized Controlled Trials as TopicSemaglutideGlucagon-Like Peptide 1Glucagon-Like PeptidesHypoglycemic AgentsSemaglutideChronic kidney diseasePhysical functionResistance trainingSedentary behaviorSemaglutide

Identifiers

PMID39608749
PMCPMC11875690

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.